In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens

被引：105

作者：

Biedenbach, D. J. ^{[1
]}

Bouchillon, S. K. ^{[1
]}

Hackel, M. ^{[1
]}

Miller, L. A. ^{[2
]}

Scangarella-Oman, N. E. ^{[2
]}

Jakielaszek, C. ^{[2
]}

Sahm, D. F. ^{[1
]}

机构：

[1] Int Hlth Management Associates Inc, Schaumburg, IL USA

[2] GlaxoSmithKline, Collegeville, PA USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2016年 / 60卷 / 03期

关键词：

D O I：

10.1128/AAC.02820-15

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Gepotidacin inhibits bacterial DNA replication through a mode different from that of fluoroquinolones. Gepotidacin and comparators were tested by broth and agar dilution against clinical isolates. The in vitro activities of gepotidacin were comparable against methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) isolates (MIC90, 0.5 mu g/ml). The gepotidacin MIC(90)s were as follows (in micrograms per milliliter) for the indicated bacteria: Streptococcus pyogenes, 0.25; Escherichia coli, 2; Moraxella catarrhalis, <= 0.06; Streptococcus pneumoniae (0.25), Haemophilus influenzae, 1; Clostridium perfringens, 0.5; and Shigella spp., 1, including levofloxacin-resistant subsets. Gepotidacin warrants further investigation for clinical development.

引用

页码：1918 / 1923

页数：6

共 12 条

[1]

[Anonymous], 2015, Methods for Antimicrobial Dilution and Disk Susceptibility Testing of Infrequently Isolated or Fastidious Bacteria, V3rd

[2]

[Anonymous], 2012, METH DIL ANT SUSC TE

[3] Type IIA topoisomerase inhibition by a new class of antibacterial agents [J].

Bax, Benjamin D. ;

Chan, Pan F. ;

Eggleston, Drake S. ;

Fosberry, Andrew ;

Gentry, Daniel R. ;

Gorrec, Fabrice ;

Giordano, Ilaria ;

Hann, Michael M. ;

Hennessy, Alan ;

Hibbs, Martin ;

Huang, Jianzhong ;

Jones, Emma ;

Jones, Jo ;

Brown, Kristin Koretke ;

Lewis, Ceri J. ;

May, Earl W. ;

Saunders, Martin R. ;

Singh, Onkar ;

Spitzfaden, Claus E. ;

Shen, Carol ;

Shillings, Anthony ;

Theobald, Andrew J. ;

Wohlkonig, Alexandre ;

Pearson, Neil D. ;

Gwynn, Michael N. .

NATURE, 2010, 466 (7309) :935-U51

[4]

Bouchillon SK, 2013, 53 INT C ANT AG CHEM, pF

[5]

CLSI, 2015, CLSI Document M100-S25

[6]

CLSI, 2012, M11A8 CLSI

[7] Novel compounds targeting bacterial DNA topoisomerase/DNA gyrase [J].

Ehmann, David E. ;

Lahiri, Sushmita D. .

CURRENT OPINION IN PHARMACOLOGY, 2014, 18 :76-83

[8] Fluoroquinolone-Gyrase-DNA Complexes TWO MODES OF DRUG BINDING [J].

Mustaev, Arkady ;

Malik, Muhammad ;

Zhao, Xilin ;

Kurepina, Natalia ;

Luan, Gan ;

Oppegard, Lisa M. ;

Hiasa, Hiroshi ;

Marks, Kevin R. ;

Kerns, Robert J. ;

Berger, James M. ;

Drlica, Karl .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (18) :12300-12312

[9]

Pfizer Inc., 2010, TYG FDA PROD INF

[10] Determination of Disk Diffusion and MIC Quality Control Guidelines for GSK2140944, a Novel Bacterial Type II Topoisomerase Inhibitor Antimicrobial Agent [J].

Ross, James E. ;

Scangarella-Oman, Nicole E. ;

Flamm, Robert K. ;

Jones, Ronald N. .

JOURNAL OF CLINICAL MICROBIOLOGY, 2014, 52 (07) :2629-2632

← 1 2 →